Donepezil a smart choice for mild-to-moderate AD in the UK

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.603, 2010-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Galantamine beneficial in mild-to-moderate AD

Inpharma, Vol. 1, Iss. 1250, 2000-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Donepezil is better tolerated than rivastigmine in mild-to-moderate Alzheimer's disease

Inpharma, Vol. 1, Iss. 1258, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer's Disease: A UK Evaluation Using Discrete-Event Simulation

By Getsios Denis

PharmacoEconomics, Vol. 28, Iss. 5, 2010-05 ,pp. : 411-427

Adis International

Access to resources Recommend Favorite

Apolipoprotein E4 (ApoE4) genotype and/or gender do not appear to predict a response to donepezil in patients with mild-to-moderate Alzheimer's disease

Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Salmeterol/fluticasone of value for mild-to-moderate asthma

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite